Ontario HIV Treatment Network; ; Dalla Lana School of Public Health, University of Toronto;
Public Health Laboratories, Public Health Ontario; ; Department of Microbiology, Mount Sinai Hospital; ; Department of Laboratory Medicine and Pathobiology, University of Toronto;
Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):17-22. doi: 10.1155/2015/689671.
Internationally, there is a growing recognition that hepatitis C virus (HCV) may be sexually transmitted among HIV-positive men who have sex with men (MSM).
To report the first Canadian estimate of HCV seroincidence in 2000 to 2010 and its risk factors among HIV-positive MSM with no known history of injection drug use.
Data from the Ontario HIV Treatment Network Cohort Study, an ongoing cohort of individuals in HIV care in Ontario, were analyzed. Data were obtained from medical charts, interviews and record linkage with the provincial public health laboratories. The analysis was restricted to 1534 MSM who did not report injection drug use and had undergone ≥2 HCV antibody tests, of which the first was negative (median 6.1 person-years [PY] of follow-up; sum 9987 PY).
In 2000 to 2010, 51 HCV seroconversions were observed, an overall incidence of 5.1 per 1000 PY (95% CI 3.9 to 6.7). Annual incidence varied from 1.6 to 8.9 per 1000 PY, with no statistical evidence of a temporal trend. Risk for seroconversion was elevated among men who had ever had syphilis (adjusted HR 2.5 [95% CI 1.1 to 5.5) and men who had acute syphilis infection in the previous 18 months (adjusted HR 2.8 [95% CI 1.0 to 7.9]). Risk was lower for men who had initiated antiretroviral treatment (adjusted HR 0.49 [95% CI 0.25 to 0.95]). There were no statistically significant effects of age, ethnicity, region, CD4 cell count or HIV viral load.
These findings suggest that periodic HCV rescreening may be appropriate in Ontario among HIV-positive MSM. Future research should seek evidence whether syphilis is simply a marker for high-risk sexual behaviour or networks, or whether it potentiates sexual HCV transmission among individuals with HIV.
国际上越来越多的人认识到,艾滋病毒(HIV)阳性的男男性行为者(MSM)之间可能会发生丙型肝炎病毒(HCV)的性传播。
报告加拿大在 2000 年至 2010 年期间首次对无已知注射毒品使用史的 HIV 阳性 MSM 中 HCV 血清发生率及其危险因素的估计。
对安大略省艾滋病毒治疗网络队列研究的资料进行了分析,该研究是安大略省艾滋病毒护理中人群的一个正在进行的队列研究。数据来自病历、访谈和与省级公共卫生实验室的记录链接。分析仅限于 1534 名未报告注射毒品使用且至少进行了 2 次 HCV 抗体检测的 MSM,其中首次检测结果为阴性(中位随访时间 6.1 人年[PY];总随访时间 9987PY)。
在 2000 年至 2010 年期间,观察到 51 例 HCV 血清学转换,总发生率为 5.1/1000PY(95%CI 3.9 至 6.7)。每年的发病率从 1.6 至 8.9/1000PY 不等,没有时间趋势的统计学证据。曾患有梅毒(调整后的 HR 2.5 [95%CI 1.1 至 5.5)和过去 18 个月内患有急性梅毒感染的男性(调整后的 HR 2.8 [95%CI 1.0 至 7.9))血清转换的风险增加。开始接受抗逆转录病毒治疗的男性(调整后的 HR 0.49 [95%CI 0.25 至 0.95))的风险较低。年龄、种族、地区、CD4 细胞计数或 HIV 病毒载量对风险没有统计学意义的影响。
这些发现表明,在安大略省,HIV 阳性 MSM 可能需要定期进行 HCV 再筛查。未来的研究应该寻求证据,以确定梅毒是否仅是高危性行为或网络的一个标志,还是它是否会增强 HIV 感染者之间的 HCV 性传播。